Cambrex Corporation (CBM) : American Capital Management Inc scooped up 75,016 additional shares in Cambrex Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 277,818 shares of Cambrex Corporation which is valued at $13,274,144.Cambrex Corporation makes up approximately 1.06% of American Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Her Majesty The Queen In Right Of The Province Of Alberta… sold out all of its stake in CBM during the most recent quarter. The investment firm sold 14,770 shares of CBM which is valued $705,711. Tealwood Asset Management Inc added CBM to its portfolio by purchasing 44,385 company shares during the most recent quarter which is valued at $2,326,218. Cambrex Corporation makes up approx 1.00% of Tealwood Asset Management Inc’s portfolio.Louisiana State Employees Retirement System boosted its stake in CBM in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 14,200 shares of Cambrex Corporation which is valued at $736,554. Cambrex Corporation makes up approx 0.04% of Louisiana State Employees Retirement System’s portfolio.First Quadrant L Pca boosted its stake in CBM in the latest quarter, The investment management firm added 68,200 additional shares and now holds a total of 119,900 shares of Cambrex Corporation which is valued at $7,056,115. Cambrex Corporation makes up approx 0.15% of First Quadrant L Pca’s portfolio.Eqis Capital Management boosted its stake in CBM in the latest quarter, The investment management firm added 2,661 additional shares and now holds a total of 65,847 shares of Cambrex Corporation which is valued at $3,823,077. Cambrex Corporation makes up approx 0.25% of Eqis Capital Management’s portfolio.
Cambrex Corporation closed down -0.6 points or -1.24% at $47.6 with 2,48,760 shares getting traded on Monday. Post opening the session at $48.2, the shares hit an intraday low of $47.6 and an intraday high of $48.29 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Cambrex Corporation reported $0.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.55. The company had revenue of $118.22 million for the quarter, compared to analysts expectations of $112.83 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS.
Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.